Results 1 to 10 of about 74,305 (343)

Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis

Acta Dermato-Venereologica, 2023
The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh, Thorunn Elísabet Michaelsdóttir, Mattias Arvid Simon Henning, Gregor Borut Ernst Jemec, Kristina Sophie Ibler   +4 more
doaj   +2 more sources

Treatment with an Anti-CD44v10-Specific Antibody Inhibits the Onset of Alopecia Areata in C3H/HeJ Mice [PDF]

, 2000
A murine CD44v10-neutralizing antibody has been reported to impair delayed-type hypersensitivity reactions. Because alopecia areata is characterized by a delayed-type hypersensitivity-like T cell mediated immune response, we addressed the question ...
Freyschmidt-Paul, Pia, König, Arne, Happle, Rudolf, Hoffmann, Rolf, Seiter, Simone, Zöller, Margot, Ziegler, Andreas, Sundberg, John P.   +7 more
core   +3 more sources

Epidemiological Trends in Alopecia Areata at the Global, Regional, and National Levels

Frontiers in Immunology, 2022
BackgroundNo comprehensive studies have been published on the global burden of alopecia areata since 2010.ObjectiveWe aimed to measure the global, regional, and national incidence of alopecia areata and disability-adjusted life-years (DALYs) by age, sex,
Haifeng Wang, Lifang Pan, Yanfeng Wu
doaj   +2 more sources

Adiponectin as a novel biomarker of disease severity in alopecia areata

Scientific Reports, 2021
The frequent coexistence of obesity and metabolic syndrome in patients with alopecia areata may indicate the common pathogenetic pathway in these conditions with an important role of adipokines.
Anna Stochmal, Anna Waśkiel-Burnat, Sylwia Chrostowska, Michał Zaremba, Adriana Rakowska, Joanna Czuwara, Lidia Rudnicka   +6 more
doaj   +2 more sources

Janus Kinase Inhibitors for Alopecia Areata

JAMA Network Open, 2023
This systematic review and meta-analysis assesses outcomes from 7 randomized clinical trials, including changes in severity and adverse events, associated with use of JAK inhibitors among adults with alopecia areata.
Ming Liu, Ya Gao, Yuan Yuan, Kelu Yang, Caiyi Shen, Jiancheng Wang, Jinhui Tian   +6 more
semanticscholar   +2 more sources

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

American Journal of Clinical Dermatology, 2023
Alopecia areata (AA) is an autoimmune disease that causes patchy hair loss on the scalp, face, and body. Baricitinib is a Janus kinase inhibitor that is approved to treat AA in several countries, based on results from two studies, BRAVE-AA1 and BRAVE-AA2.
O. Kwon, M. Senna, Rodney D Sinclair, T. Ito, Y. Dutronc, Chen-Yen Lin, G. Yu, C. Chiasserini, J. Mccollam, Wen-Shuo Wu, B. King   +10 more
semanticscholar   +1 more source

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment

Przegląd Dermatologiczny, 2023
The existence of two types of alopecia areata is suggested (probably genetically different): early-onset, with more severe symptoms, longer disease duration, higher tendency to relapse, often with a positive family history, and late-onset, in which the ...
Adriana Rakowska, Lidia Rudnicka, Małgorzata Olszewska, Beata Bergler-Czop, Joanna Czuwara, Ligia Brzezińska-Wcisło, Joanna Narbutt, Waldemar Placek, Barbara Zegarska   +8 more
doaj   +1 more source

Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

JAMA dermatology, 2023
Key Points Question What is the contemporary prevalence and incidence of alopecia areata (AA), alopecia totalis, and alopecia universalis in the US? Findings In this cohort study of a nationwide US employer-sponsored insurance population, AA prevalence ...
A. Mostaghimi, Wei Gao, M. Ray, Lauren Bartolome, Travis Wang, C. Carley, Nicolae Done, E. Swallow   +7 more
semanticscholar   +1 more source

Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Society of Dermatology. Part 2: Treatment

Przegląd Dermatologiczny, 2023
The treatment goal in alopecia areata is induction of hair regrowth and halting the progression of the disease. Treatment decisions depend on the severity of the alopecia areata as assessed by the Severity of Alopecia Tool (SALT) or the Alopecia Areata ...
Adriana Rakowska, Lidia Rudnicka, Małgorzata Olszewska, Beata Bergler-Czop, Joanna Czuwara, Ligia Brzezińska-Wcisło, Joanna Narbutt, Waldemar Placek, Barbara Zegarska   +8 more
doaj   +1 more source

Alopecia Areata: An Updated Review for 2023

Journal of Cutaneous Medicine and Surgery, 2023
Alopecia areata is an immunemediated condition leading to nonscarring alopecia of the scalp and other hairbearing areas of the body. It affects up to 2% of the global population.1 It can affect all ages, but the prevalence appears higher in children ...
C. Sibbald
semanticscholar   +1 more source